Linear Diagnostics Limited

Founded in 2011 by Matthew Hicks and Tim Dafforn, and based in Birmingham, UK, Linear Diagnostics Limited offers a novel technology platform that can be used in a wide range of diagnostic applications. Linear Diagnostics has partnered with several end-users such as clinical microbiology, food producers, and defense medicine. Linear Diagnostics’ team comprises of experienced medical diagnostic professionals and healthcare investors. As of 2021, the company staffs 21 employees.

In 2021, Linear Diagnostics Limited raised GBP 0. 8 million in venture funding led by new investor Midlands Engine Investment Fund, with participation from other new investors. The firm uses linear dichroism which enables the rapid detection of multiple targets using a disposable cartridge run on a small instrument designed for rapid Point-of-Care testing for sexually transmitted infections (STIs) and other infectious diseases. Linear Diagnostics’ solutions initially focused on sexually transmitted infections and now include Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and in vitro diagnostics markets within and beyond STIs.

The company developed a rapid test for CT/NG which can detect multiple infections in the same sample in around 15 minutes by labeling each infection indicator with a different colored dye. The company’s solutions can be used in high-value sectors such as health, food, defense, and security. The company plans on utilizing the funds raised in venture funding for the ongoing development of the company’s high-speed platform for point-of-care diagnostics.